1,603,056 Shares in Outset Medical, Inc. $OM Acquired by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. made a significant investment of $17.73 million in Outset Medical, acquiring 1,603,056 shares and owning approximately 44.59% of the company post-investment.
• Wall Street analysts have mixed ratings for Outset Medical, with a consensus average rating of "Buy" and a price target of $24.67, while estimates range from a low of $22 to a high of $37.
• Outset Medical's stock performance shows a 12-month low of $5.85 and a high of $25.35, alongside a current market cap of $252.33 million.

T. Rowe Price Investment Management Inc. acquired a new stake in Outset Medical, Inc. (NASDAQ:OM - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,603,056 shares of the company's stock, valued at approximately $17,730,000. T. Rowe Price Investment Management Inc. owned 44.59% of Outset Medical at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Two Sigma Securities LLC boosted its stake in shares of Outset Medical by 190.0% in the fourth quarter. Two Sigma Securities LLC now owns 42,477 shares of the company's stock worth $47,000 after acquiring an additional 27,830 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Outset Medical in the fourth quarter worth approximately $50,000. TD Asset Management Inc acquired a new stake in shares of Outset Medical in the first quarter worth approximately $589,000. Two Sigma Investments LP boosted its stake in shares of Outset Medical by 36.0% in the fourth quarter. Two Sigma Investments LP now owns 488,602 shares of the company's stock worth $542,000 after acquiring an additional 129,334 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Outset Medical in the fourth quarter worth approximately $174,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on OM. Scotiabank raised Outset Medical to a "strong-buy" rating in a research note on Thursday, May 15th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $22.00 price target on shares of Outset Medical in a research note on Tuesday, August 19th. Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, BTIG Research set a $37.00 price objective on Outset Medical and gave the stock a "buy" rating in a research note on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $24.67.

Outset Medical Stock Performance

NASDAQ:OM traded down $0.04 during mid-day trading on Thursday, reaching $13.92. 91,775 shares of the stock were exchanged, compared to its average volume of 223,937. The company has a 50 day simple moving average of $16.94 and a 200-day simple moving average of $14.65. The stock has a market capitalization of $247.36 million, a P/E ratio of -0.69 and a beta of 2.14. The company has a quick ratio of 6.05, a current ratio of 7.47 and a debt-to-equity ratio of 0.63. Outset Medical, Inc. has a 1 year low of $5.85 and a 1 year high of $25.35.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.